Editor's Corner—For the first PD-1xVEGF's sake, Summit must submit to Big Pharma, stat
10th September 2025 Uncategorised 0The highly debatable HARMONi data, along with the trial design flaws and the unfortunate execution they reflect, plus a rapidly evolving competitive landscape, all point to one conclusion: Summit must partner with a Big Pharma company as soon as possible.
read more
